We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Plasma Neurofilament Light Predicts All-Cause Mortality Risk

By LabMedica International staff writers
Posted on 21 Jun 2022
Print article
Image: Simoa HD-X Analyzer was used to quantify plasma neurofilament light chain (Photo courtesy of Quanterix)
Image: Simoa HD-X Analyzer was used to quantify plasma neurofilament light chain (Photo courtesy of Quanterix)

Neurofilament light chain (NfL) is a cytoskeletal protein component exclusively expressed in neurons that is released into the extracellular fluids, including blood, during neuroaxonal damage. NfL is linked to mortality in neurological disorders, remaining unexplored in population studies.

NfL reflects sub-cortical large-caliber axonal degeneration. Plasma NfL levels correlate strongly with cerebrospinal fluid (CSF) NfL levels, adding to its clinical utility in differential diagnoses for dementias and other neurodegenerative diseases. Therefore, plasma NfL measurements are advantageous given the invasiveness of CSF assessments and feasibility for long-term monitoring.

Scientists at the National Institute on Aging (Baltimore, MD, USA) collected longitudinal data from 694 participants in the Healthy Aging in Neighborhoods of Diversity Across the Life Span study (HANDLS, mean age first visit [v1]: 47.8 years, 42% male, 55.8% African American). Fasting blood samples were collected between 9:30 am and 11:30 am into EDTA blood collection tubes.

Plasma NfL was measured prospectively at three visits. Plasma NfL levels were quantified using the Simoa NF-light Advantage Kit on a Simoa HD-X analyzer by Quanterix (Billerica, MA, USA). Total cholesterol (mg/dL), HDL cholesterol (mg/dL), high-sensitivity C-reactive protein (hsCRP) (mg/dL), albumin (g/dL), and glycosylated hemoglobin (HbA1c) (%) were quantified by contract laboratories (Quest Diagnostics, Chantilly, VA, USA). In this study, the δNfL is the annualized rate of change between NfLv1, NfLv2, and NfLv3, on average, when these measurements were Loge-transformed.

The team reported that most notably, men had significantly higher plasma NfL (Loge-transformed) compared to women at both visits 1 and 3. These differences remained comparable after further adjustment for age, race, and poverty status. Moreover, men were more likely than women to be pre-diabetic, with the reverse being observed in the case of diabetes. Self-reported history of cardiovascular disease (CVD) was more prevalent in women (15.9% versus 8.7%). Several continuous components of AL were higher among women, namely hsCRP, total cholesterol, and HDL cholesterol, while the reverse was observed for albumin and diastolic blood pressure (DBP). Similar patterns were observed for binary AL components. Notably, NfLv1 was shown to be a better prognostic indicator at normal hsCRP values among women, while HbA1c and δNfL interacted synergistically to determine mortality risk, overall.

The authors concluded that plasma NfL levels measured both at baseline and over time can predict all-cause mortality in women. The study was published on June 13, 2022 in the journal BMC Medicine.

Related Links:
National Institute on Aging 
Quanterix 
Quest Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more